HAMBURG, Germany, Oct. 15, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) today announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated a new discovery collaboration. Under the contract extension Evotec will provide integrated drug discovery activities, including high throughput screening, medicinal chemistry and in vitro pharmacology to discover novel, small molecular weight compounds active against an ion channel target selected by Ono. Ono will access Evotec’s ion channel drug discovery platform and expertise and Evotec will receive research funding and milestone payments.
